Literature DB >> 18595958

Clinical and genetic analysis of unclassifiable inherited bone marrow failure syndromes.

Juliana T Teo1, Robert Klaassen, Conrad V Fernandez, Rochelle Yanofsky, John Wu, Josette Champagne, Mariana Silva, Jeffrey H Lipton, Jossee Brossard, Yvan Samson, Sharon Abish, Macgregor Steele, Kaiser Ali, Uma Athale, Lawrence Jardine, John P Hand, Elena Tsangaris, Isaac Odame, Joseph Beyene, Yigal Dror.   

Abstract

OBJECTIVE: Unclassified inherited bone marrow failure syndromes are a heterogeneous group of genetic disorders that represent either new syndromes or atypical clinical courses of known inherited bone marrow failure syndromes. The relative prevalence of the unclassified inherited bone marrow failure syndromes and their characteristics and the clinical and economic challenges that they create have never been studied.
METHODS: We analyzed cases of inherited bone marrow failure syndrome in the Canadian Inherited Marrow Failure Registry that were deemed unclassifiable at study entry.
RESULTS: From October 2001 to March 2006, 39 of the 162 patients enrolled in the Canadian Inherited Marrow Failure Registry were registered as having unclassified inherited bone marrow failure syndromes. These patients presented at a significantly older age (median: 9 months) than the patients with classified inherited bone marrow failure syndrome (median: 1 month) and had substantial variation in the clinical presentations. The hematologic phenotype, however, was similar to the classified inherited bone marrow failure syndromes and included single- or multiple-lineage cytopenia, severe aplastic anemia, myelodysplasia, and malignancy. Grouping patients according to the affected blood cell lineage(s) and to the presence of associated physical malformations was not always sufficient to characterize a condition, because affected members from several families fit into different phenotypic groups. Compared with the classified inherited bone marrow failure syndromes, the patients with unclassified inherited bone marrow failure syndromes had 3.2 more specific diagnostic tests at 4.5 times higher cost per evaluated patient to attempt to categorize their syndrome. At last follow-up, only 20% of the unclassified inherited bone marrow failure syndromes were ultimately diagnosed with a specific syndrome on the basis of the development of new clinical findings or positive genetic tests.
CONCLUSIONS: Unclassified inherited bone marrow failure syndromes are relatively common among the inherited bone marrow failure syndromes and present a major diagnostic and therapeutic dilemma.

Entities:  

Mesh:

Year:  2008        PMID: 18595958     DOI: 10.1542/peds.2007-3415

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  13 in total

1.  Outcomes after related and unrelated umbilical cord blood transplantation for hereditary bone marrow failure syndromes other than Fanconi anemia.

Authors:  Renata Bizzetto; Carmen Bonfim; Vanderson Rocha; Gérard Socié; Franco Locatelli; Kawah Chan; Oscar Ramirez; Joel Stein; Samir Nabhan; Eliana Miranda; Jakob Passweg; Carmino Antonio de Souza; Eliane Gluckman
Journal:  Haematologica       Date:  2010-11-11       Impact factor: 9.941

2.  Response to comments from Drs. Alter and Rosenberg.

Authors:  Yigal Dror; Michaela Cada
Journal:  Haematologica       Date:  2015-09       Impact factor: 9.941

Review 3.  Current insights into the diagnosis and treatment of inherited bone marrow failure syndromes in China.

Authors:  Xiaofan Zhu
Journal:  Stem Cell Investig       Date:  2015-08-06

4.  Genetic panels in young patients with bone marrow failure: are they clinically relevant?

Authors:  Amy E DeZern; Robert A Brodsky
Journal:  Haematologica       Date:  2016-11       Impact factor: 9.941

5.  Single nucleotide polymorphism array analysis of bone marrow failure patients reveals characteristic patterns of genetic changes.

Authors:  Daria V Babushok; Hongbo M Xie; Jacquelyn J Roth; Nieves Perdigones; Timothy S Olson; Joshua D Cockroft; Xiaowu Gai; Juan C Perin; Yimei Li; Michele E Paessler; Hakon Hakonarson; Gregory M Podsakoff; Philip J Mason; Jaclyn A Biegel; Monica Bessler
Journal:  Br J Haematol       Date:  2013-10-14       Impact factor: 6.998

6.  Case 1: A newborn with pancytopenia.

Authors:  Isabel Cardona; Emanuela Ferretti; Thierry Daboval; Robert J Klaassen; Yigal Dror
Journal:  Paediatr Child Health       Date:  2016 Jan-Feb       Impact factor: 2.253

7.  The impact of category, cytopathology and cytogenetics on development and progression of clonal and malignant myeloid transformation in inherited bone marrow failure syndromes.

Authors:  Michaela Cada; Catherin I Segbefia; Robert Klaassen; Conrad V Fernandez; Rochelle A Yanofsky; John Wu; Yves Pastore; Mariana Silva; Jeffrey H Lipton; Josee Brossard; Bruno Michon; Sharon Abish; MacGregor Steele; Roona Sinha; Mark Belletrutti; Vicky Breakey; Lawrence Jardine; Lisa Goodyear; Lillian Sung; Mary Shago; Joseph Beyene; Preeti Sharma; Bozana Zlateska; Yigal Dror
Journal:  Haematologica       Date:  2015-02-14       Impact factor: 9.941

8.  Severe Aplastic Anemia Manifesting After Complete Remission of Acute Promyelocytic Leukemia: Is it a Fortuitous Association?

Authors:  Rajeshwari Satish Handigund; Prakash R Malur; Annasaheb J Dhumale; Akshay Bali; Maitrayee Roy; Suvarna Inumella
Journal:  Indian J Hematol Blood Transfus       Date:  2012-10-09       Impact factor: 0.900

9.  Ataxia and pancytopenia caused by a mutation in TINF2.

Authors:  Elena Tsangaris; Sally-Lin Adams; Grace Yoon; David Chitayat; Peter Lansdorp; Inderjeet Dokal; Yigal Dror
Journal:  Hum Genet       Date:  2008-11-01       Impact factor: 4.132

Review 10.  Updated Guidelines for the Treatment of Acquired Aplastic Anemia in Children.

Authors:  Nao Yoshida; Seiji Kojima
Journal:  Curr Oncol Rep       Date:  2018-06-30       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.